Abstract
Combined clinical and pharmacogenetic risk scoring model determines ACE-inhibitor treatment benefit in patients with stable coronary artery disease
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
